Jun 2026 (Q2 FY26) — Aug 13, 2026
Lucid Diagnostics Q2 FY26 — Commercialization Progress Amidst Medicare Wait
Read the full callLucid Diagnostics (LUCD) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Lucid Diagnostics earnings: last reported Thu, 13 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 1.5 | +26.7% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -868.5 | +110.4 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -11.7 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$0.38 −20.83% · −$0.1
Performance −67.8% 1Y
1Y: $1.18 on 17 Oct 2025 → $0.38. High $1.47 (26 Feb 2026), low $0.38 (19 Oct 2026).
- Previous close
- $0.48
- 52-week range
- $0.38 – $1.47
- One year
- −69.60%
Overview
- Symbol
- LUCD
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Lucid Diagnostics earnings calls (LUCD)
Financials
What the filings say
Net profit, year on year: −163% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 |
| Expenses | — | — | 13 | 13 | — | — | 13 | 14 |
| Operating profit | -12 | -12 | -12 | -11 | -12 | -14 | -12 | -13 |
| Operating margin | −997.8% | −1033.8% | −1508.1% | −978.9% | −971.0% | −931.5% | −964.5% | −868.5% |
| Other income | — | — | -14 | 7 | — | — | -2 | 1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | -12 | -12 | -27 | -4 | -10 | -16 | -14 | -12 |
| Tax rate | — | — | 0.0% | 0.0% | — | — | 0.0% | 0.0% |
| Net profit | -12 | -12 | -27 | -4 | -10 | -16 | -14 | -12 |
| EPS ($ per share) | -0.25 | — | -0.52 | -0.08 | -0.10 | — | -0.17 | -0.08 |
| Line item | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -14 | -42 | -98 | -151 | -204 | -274 |
| Total liabilities | 16 | 4 | 9 | 30 | 25 | 30 |
| Fixed assets | — | 1 | 2 | 1 | 1 | 1 |
| Total assets | 2 | 59 | 33 | 27 | 31 | 40 |
| Line item | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Cash from operations | -6 | -18 | -30 | -33 | -44 | -46 |
| Cash from investing | — | -1 | -4 | -0 | -1 | -0 |
| Cash from financing | 6 | 72 | 3 | 29 | 48 | 59 |
| Net cash flow | -0 | 54 | -31 | -4 | 3 | 12 |
| Capital expenditure | — | -1 | -3 | — | -0 | -0 |
| Free cash flow | — | -19 | -33 | — | -44 | -47 |
Insider filings
12 filings between Feb 20, 2026 and May 20, 2026.
Open market
decisions to buy or sellPurchases
$245.3K
1 purchase by 1 insider
Sales
None
No insider sold shares.
Compensation
not trading decisions- 11
- Award — granted as compensation
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Matheis Dennis | $245.3K | — | May 20, 2026 |
Latest filings (26)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| May 20, 2026 | Matheis Dennis Director | Purchase | 245,000 | $245.3K |
| Feb 20, 2026 | Gordon Michael Adam General Counsel and Secretary | Award | 300,000 | $0 |
| Feb 20, 2026 | O'Neil Shaun President and COO | Award | 620,000 | $0 |
| Feb 20, 2026 | MCGRATH DENNIS M Chief Financial Officer | Award | 470,000 | $0 |
| Feb 20, 2026 | Cox James L Director | Award | 123,000 | $0 |
| Feb 20, 2026 | Lapidus Stanley Director | Award 10b5-1 plan | 123,000 | $0 |
| Feb 20, 2026 | PALUMBO JOHN R Director | Award | 123,000 | $0 |
| Feb 20, 2026 | SOKOLOV JACQUE J Director | Award | 123,000 | $0 |
| Feb 20, 2026 | Sparks Ronald M Director | Award | 123,000 | $0 |
| Feb 20, 2026 | White Debra Director | Award | 123,000 | $0 |
| Feb 20, 2026 | Matheis Dennis Director | Award | 123,000 | $0 |
| Feb 20, 2026 | Aklog Lishan Chief Executive Officer | Award | 2,170,000 | $0 |
| Aug 20, 2025 | Matheis Dennis Director | Purchase | 100,000 | $101.8K |
| May 22, 2025 | Matheis Dennis Director | Purchase | 33,218 | $43.8K |
| May 21, 2025 | Matheis Dennis Director | Purchase | 129,684 | $171.5K |
| May 20, 2025 | Matheis Dennis Director | Purchase | 187,098 | $242.3K |
| Feb 20, 2025 | Sparks Ronald M Director | Award | 112,800 | $0 |
| Feb 20, 2025 | White Debra Director | Award | 112,800 | $0 |
| Feb 20, 2025 | Gordon Michael Adam General Counsel and Secretary | Award | 300,000 | $0 |
| Feb 20, 2025 | MCGRATH DENNIS M Chief Financial Officer | Award | 300,000 | $0 |
| Feb 20, 2025 | Cox James L Director | Award | 112,800 | $0 |
| Feb 20, 2025 | Matheis Dennis Director | Award | 112,800 | $0 |
| Feb 20, 2025 | Lapidus Stanley Director | Award 10b5-1 plan | 112,800 | $0 |
| Feb 20, 2025 | SOKOLOV JACQUE J Director | Award | 112,800 | $0 |
| Feb 20, 2025 | Aklog Lishan Chief Executive Officer | Award | 300,000 | $0 |
| Feb 20, 2025 | O'Neil Shaun President and COO | Award | 300,000 | $0 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Lucid Diagnostics Inc.
Free account. Everything above stays public.
Write why you follow Lucid Diagnostics Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading